Bayer's Eylea hits main goal in DME trials

In two Phase III trials, Bayer's VEGF Trap-Eye drug, also called Eylea, met its primary endpoint in treating diabetic macular edema, the company said. The firm co-develops the medication with Regeneron, which plans to seek U.S. marketing approval this year for the treatment of diabetic macular edema.

View Full Article in:

Reuters · Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Actuary
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
MetLife
Bridgewater, NJ